Richard J Zarbo1, M Elizabeth H Hammond. 1. Department of Pathology, Henry Ford Hospital and Medical Group, Detroit, Mich 48202, USA. rzarbo1@hfhs.org
Abstract
CONTEXT: Practicing pathologists often encounter controversial clinical issues and nonstandardized laboratory approaches to the evolving science of predictive/prognostic tumor marker assays. This dilemma becomes especially acute when the assay is the sole determinant for selection of a specific therapy. OBJECTIVES: To summarize the areas of practical agreement and identify opportunities for improvement in Her-2/neu testing of breast cancer. DESIGN: The College of American Pathologists created a new comprehensive education model, called Strategic Science, with expert speakers integrating new and evolving basic, clinical, and scientific issues of Her-2/neu testing with aspects of laboratory management. SETTING: Symposium held May 4 and 5, 2002, in Rosemont, Ill. PARTICIPANTS: Ten speakers and more than 100 attendees. RESULTS: Components addressed were new technology assessment, practice guidelines, quality assurance, regulatory compliance, risk and liability, billing and coding, cost analysis, consultation, information management, and results reporting. CONCLUSIONS: This Strategic Science symposium derived areas of practical agreement, defined the current state-of-the-art, and identified areas for improvement in Her-2/neu testing.
CONTEXT: Practicing pathologists often encounter controversial clinical issues and nonstandardized laboratory approaches to the evolving science of predictive/prognostic tumor marker assays. This dilemma becomes especially acute when the assay is the sole determinant for selection of a specific therapy. OBJECTIVES: To summarize the areas of practical agreement and identify opportunities for improvement in Her-2/neu testing of breast cancer. DESIGN: The College of American Pathologists created a new comprehensive education model, called Strategic Science, with expert speakers integrating new and evolving basic, clinical, and scientific issues of Her-2/neu testing with aspects of laboratory management. SETTING: Symposium held May 4 and 5, 2002, in Rosemont, Ill. PARTICIPANTS: Ten speakers and more than 100 attendees. RESULTS: Components addressed were new technology assessment, practice guidelines, quality assurance, regulatory compliance, risk and liability, billing and coding, cost analysis, consultation, information management, and results reporting. CONCLUSIONS: This Strategic Science symposium derived areas of practical agreement, defined the current state-of-the-art, and identified areas for improvement in Her-2/neu testing.
Authors: Helen Swede; David I Gregorio; Susan H Tannenbaum; Jessica A Brockmeyer; Christine Ambrosone; Lori L Wilson; Mellisa A Pensa; Lou Gonsalves; Richard G Stevens; Carolyn D Runowicz Journal: Clin Breast Cancer Date: 2011-05-12 Impact factor: 3.225
Authors: M Dietel; I O Ellis; H Höfler; H Kreipe; H Moch; A Dankof; K Kölble; G Kristiansen Journal: Virchows Arch Date: 2007-06-12 Impact factor: 4.064
Authors: Hiroaki Nitta; Brian D Kelly; Mary Padilla; Nikolaus Wick; Patrick Brunhoeber; Isaac Bai; Shalini Singh; Jim Ranger-Moore; Chris Bieniarz; Hitoshi Tsuda; Thomas M Grogan Journal: Diagn Pathol Date: 2012-05-30 Impact factor: 2.644
Authors: L Del Mastro; P Bruzzi; G Nicolò; G Cavazzini; A Contu; M D'Amico; A Lavarello; F Testore; B Castagneto; E Aitini; L Perdelli; C Bighin; R Rosso; Marco Venturini Journal: Br J Cancer Date: 2005-07-11 Impact factor: 7.640